End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
12,360 KRW | +1.73% | +0.16% | +7.76% |
Jan. 29 | Zimbabwe launches door-to-door cholera vaccination campaign | RE |
2023 | Pop Biotechnologies and Eubiologics' Eucorvac-19 Vaccine Hits Target in Phase 3 Trial | CI |
Sales 2024 * | 116B 84.91M | Sales 2025 * | 128B 93.7M | Capitalization | 451B 330M |
---|---|---|---|---|---|
Net income 2024 * | 29B 21.23M | Net income 2025 * | 34B 24.89M | EV / Sales 2024 * | 4.01 x |
Net Debt 2024 * | 14B 10.25M | Net Debt 2025 * | 14B 10.25M | EV / Sales 2025 * | 3.63 x |
P/E ratio 2024 * |
15.3
x | P/E ratio 2025 * |
13.3
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 80.14% |
1 day | +1.73% | ||
1 week | +0.16% | ||
Current month | -7.69% | ||
1 month | -11.14% | ||
3 months | +0.98% | ||
6 months | +36.73% | ||
Current year | +7.76% |
Managers | Title | Age | Since |
---|---|---|---|
Yeong-Ok Baek
CEO | Chief Executive Officer | 61 | 04-12-31 |
Suk-Keun Choi
DFI | Director of Finance/CFO | 57 | 10-07-31 |
Kyeong-Ho Min
BRD | Director/Board Member | 55 | 10-11-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Suk-Keun Choi
DFI | Director of Finance/CFO | 57 | 10-07-31 |
Yeong-Ok Baek
CEO | Chief Executive Officer | 61 | 04-12-31 |
Kyeong-Ho Min
BRD | Director/Board Member | 55 | 10-11-30 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-28 | 12,360 | +1.73% | 196,249 |
24-05-27 | 12,150 | -0.25% | 229,199 |
24-05-24 | 12,180 | +1.08% | 125,662 |
24-05-23 | 12,050 | -0.25% | 141,763 |
24-05-22 | 12,080 | -2.11% | 278,519 |
End-of-day quote Korea S.E., May 27, 2024
More quotesEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+7.76% | 326M | |
-2.49% | 90.28B | |
-1.97% | 39.5B | |
-15.47% | 31.71B | |
+61.28% | 26.41B | |
-22.81% | 14.34B | |
-8.82% | 12.89B | |
-11.77% | 11.8B | |
-45.97% | 10.95B | |
+3.30% | 8.85B |
- Stock Market
- Equities
- A206650 Stock